Dublin, June 27, 2018 (GLOBE NEWSWIRE) -- The "Circulating Tumor Cell (CTC) Diagnostics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Circulating Tumor Cell (CTC) Diagnostics in US$. The report profiles 48 companies including many key and niche players such as:
- ApoCell, Inc. (US)
- Biocep Ltd. (Israel)
- Biocept, Inc. (US)
- Biofluidica Microtechnologies LLC (US)
- Celltraffix Inc. (US)
- Clearbridge Biomedics (Singapore)
- Creatv Microtech, Inc. (US)
- Cynvenio Biosystems, Inc. (US)
- Epic Biosciences Inc. (US)
- Fluxion Biosciences, Inc. (US)
- Ikonisys, Inc. (US)
- IVDiagnostics, Inc. (US)
- Janssen Diagnostics LLC (US)
- QIAGEN Hannover GmbH (Germany)
- RARECELLS SAS (Italy)
- ScreenCell (France)
- STEMCELL Technologies, Inc. (Canada)
Key Topics Covered
1. INDUSTRY OVERVIEW Market Outlook Clinical Relevance of CTCs CTC Detection Real-Time Liquid Biopsy' Scores Over Surgical Biopsy Major Challenges in CTC Diagnostics Need for CTC Enrichment and Popular Methods CTC Enrichment Techniques Select Available CTC Detection Technologies Select CTC Isolation Systems A Brief Comparison CTC Identification Various Approaches CTC Identification Approaches List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type CellSearch System The First FDA Approved Automated Enrichment/Isolation Technique Rising Incidence of Cancer An Opportunity Indicator Cancer Prone Sites based on Age 2. MARKET TRENDS AND DRIVERS Liquid Biopsy the New Buzzword in Healthcare Select Companies Active in Cancer Liquid Biopsy CTCs for Personalized Cancer Treatment Microfluidic Chip-based Technologies A Promising Avenue for Cancer Diagnosis CTC Microdevices Hog the Limelight Increasing Research Reveal Further Complexities to CTC Composition and Behavior EpCAM Glycoprotein Insufficient for CTC Detection New Isolation Techniques Show Promise in Detecting EpCAM- Negative CTCs Physical Property-based Enrichment Technologies Lose Fizz Evidence in Favor CTC Heterogeneity Gains Strength CTC Clusters Raise Research Interest Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings Limitations of CTC Technology for Point-of-Care Testing CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis Limited Biomarkers Utilized In CTC Diagnostics A Threat to Market Growth? Select Research Findings in Recent Years Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity NBiomics Makes its Contribution to CTC Diagnosis Researchers at University of Michigan Develop Revolutionary Capture CTCs Method Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis Gold Nanoparticles Help in the Detection of CTCs 3. MEDICAL DIAGNOSTICS MARKET A CONCEPTUAL OVERVIEW Clinical Diagnostics Molecular Diagnostics Growth Drivers Molecular Diagnostics for Lymphoid Malignancies Market Trends & Issues Global Molecular Diagnostics on a High Growth Curve Automation Driving Global Market Molecular Diagnostics: Marking Convergence of Numerous Technologies Aging Population, Disease Incidence Fundamental Drivers of Growth Pharmaceutical Firms Carving their Niche in the Molecular Diagnostics Market Limited Reimbursements by Third Party Payers A Stumbling Block Molecular Diagnostics and Intellectual Property Business Opportunities in the Offing Medical Training and Practice Challenges Hurdles All the Way for Companies Eyeing Molecular Diagnostics Integration of Molecular Diagnostics into Therapeutics Molecular Diagnostics Moving from Centralization to Decentralization 4. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS Enrichment, Identification and Characterization Methods 5. PRODUCT LAUNCHES AND INTRODUCTIONS Vortex Biosciences Launches VTX-1 Liquid Biopsy System Vortex Biosciences Secures CE Mark and FDA Class I Registration for VTX-1 Liquid Biopsy System Fluxion Biosciences Roll Out New CTC Recovery Kits Biocept Launches c-MET Amplification Detection Test Biocept Launches ROS1 Test for Identifying Suitable Therapeutic Targets for NSCLC 6. RECENT INDUSTRY ACTIVITY Menarini-Silicon Inks Agreement to Take Over CELLSEARCH CTC Assets Cancer Genetics and ApoCell Team Up for Cancer Profiling and Therapy Selection Genomic Health Signs Commercial Agreement with Epic Sciences for AR-V7 Liquid Biopsy Test BGI Joins Hands with Clearbridge BioMedics to Market CTC Products in China Abnova Secures License to CSV Monoclonal Antibody for CTC Detection Sorrento Secures License to CytoLumina's NanoVelcro CTC Profiling Assay Janssen Announces Utility of CELLSEARCH System in PD-L1 Expression Detection on CTCs Qiagen Acquires AdnaGen's CTC Enrichment Technology Tokai Inks Deal with Qiagen for Licensing CTC Enrichment Technology ScreenCell Enters Collaborative Study for Evaluating CTC Enrichment Capability of ScreenCell Products 7. FOCUS ON SELECT PLAYERS ApoCell, Inc. (US) Biocep Ltd. (Israel) Biocept, Inc. (US) Biofluidica Microtechnologies LLC (US) Celltraffix Inc. (US) Clearbridge Biomedics (Singapore) Creatv Microtech, Inc. (US) Cynvenio Biosystems, Inc. (US) Epic Biosciences Inc. (US) Fluxion Biosciences, Inc. (US) Ikonisys, Inc. (US) IVDiagnostics, Inc. (US) Janssen Diagnostics LLC (US) QIAGEN Hannover GmbH (Germany) RARECELLS SAS (Italy) ScreenCell (France) STEMCELL Technologies, Inc. (Canada) 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 48
- The United States (31)
- Canada (3)
- Europe (10)
- France (1)
- Germany (6)
- The United Kingdom (2)
- Italy (1)
- Asia-Pacific (Excluding Japan) (3)
- Middle East (1)
For more information about this report visit https://www.researchandmarkets.com/research/5...lobal?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Diagnostics, Biomarkers
